ENZC (Enzolytics) Other Financing: $-0.04 Mil (TTM As of Jun. 2011)


What is Enzolytics Other Financing?

Enzolytics ENZC -10.00% Other Financing is $-0.04 Mil as of Jun. 2011.

Enzolytics's Other Financing for the three months ended in Jun. 2011 was $-0.04 Mil.

Enzolytics's Other Financing for the trailing twelve months (TTM) ended in Jun. 2011 was $-0.04 Mil.

Enzolytics Other Financing Historical Data

* Premium members only.

The historical data trend for Enzolytics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics Other Financing Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
Other Financing
0.00 0.00 0.00 0.00

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.37 -0.37 0.00 -0.04

Enzolytics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.04 Mil mean?
Enzolytics (ENZC) has a Other Financing of $-0.04 Mil as of Jun. 2011. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Enzolytics and its competitors.
Is Enzolytics' Other Financing too high?
Enzolytics' current Other Financing is $-0.04 Mil.
How does Enzolytics' Other Financing compare to competitors?
Enzolytics' Other Financing of $-0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Enzolytics and its competitors. Enzolytics's current Other Financing is $-0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current Other Financing of $-0.04 Mil. The current Other Financing is $-0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Enzolytics (ENZC), the current Other Financing is $-0.04 Mil as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.